Denosumab biosimilar HLX14 versus EU-denosumab in postmenopausal women at high fracture risk: a randomized, double-blind, multicenter phase 3 trial

Li Xin, Zhiyong Li, Jun Zhang, Qun Xia, Ping Jin, Qingyun Xue, Xin Zheng, Xin Tang, Zhong Yuan, Lin Shen, Peng Duan, Yawei Zhang, Yanan Huo, Bingwu Wang, Zhifeng Cheng, Youliang Cao, Liping Li, Yuhong Zeng, Lizhen Lan, Yibing Lu, Li Mao, Zhan Zhang, Cong Chen, Qingyu Wang, Haoyu Yu, Jing Li, Jun Zhu

Open source

DOI: 10.1007/s00198-026-08262-5
Published: 2026-11-04
Container: Osteoporosis International
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00198-026-08262-5,
  title = {Denosumab biosimilar HLX14 versus EU-denosumab in postmenopausal women at high fracture risk: a randomized, double-blind, multicenter phase 3 trial},
  author = {Li Xin and Zhiyong Li and Jun Zhang and Qun Xia and Ping Jin and Qingyun Xue and Xin Zheng and Xin Tang and Zhong Yuan and Lin Shen and Peng Duan and Yawei Zhang and Yanan Huo and Bingwu Wang and Zhifeng Cheng and Youliang Cao and Liping Li and Yuhong Zeng and Lizhen Lan and Yibing Lu and Li Mao and Zhan Zhang and Cong Chen and Qingyu Wang and Haoyu Yu and Jing Li and Jun Zhu},
  year = {2026},
  journal = {Osteoporosis International},
  doi = {10.1007/s00198-026-08262-5},
  url = {https://doi.org/10.1007/s00198-026-08262-5}
}

RIS

TY  - JOUR
TI  - Denosumab biosimilar HLX14 versus EU-denosumab in postmenopausal women at high fracture risk: a randomized, double-blind, multicenter phase 3 trial
AU  - Li Xin
AU  - Zhiyong Li
AU  - Jun Zhang
AU  - Qun Xia
AU  - Ping Jin
AU  - Qingyun Xue
AU  - Xin Zheng
AU  - Xin Tang
AU  - Zhong Yuan
AU  - Lin Shen
AU  - Peng Duan
AU  - Yawei Zhang
AU  - Yanan Huo
AU  - Bingwu Wang
AU  - Zhifeng Cheng
AU  - Youliang Cao
AU  - Liping Li
AU  - Yuhong Zeng
AU  - Lizhen Lan
AU  - Yibing Lu
AU  - Li Mao
AU  - Zhan Zhang
AU  - Cong Chen
AU  - Qingyu Wang
AU  - Haoyu Yu
AU  - Jing Li
AU  - Jun Zhu
PY  - 2026
JO  - Osteoporosis International
DO  - 10.1007/s00198-026-08262-5
UR  - https://doi.org/10.1007/s00198-026-08262-5
ER  -

APA

Xin, L., Li, Z., Zhang, J., Xia, Q., Jin, P., Xue, Q., Zheng, X., Tang, X., Yuan, Z., Shen, L., Duan, P., Zhang, Y., Huo, Y., Wang, B., Cheng, Z., Cao, Y., Li, L., Zeng, Y., Lan, L., Lu, Y., Mao, L., Zhang, Z., Chen, C., Wang, Q., Yu, H., Li, J., & Zhu, J. (2026). Denosumab biosimilar HLX14 versus EU-denosumab in postmenopausal women at high fracture risk: a randomized, double-blind, multicenter phase 3 trial. Osteoporosis International. https://doi.org/10.1007/s00198-026-08262-5

Source records

crossref · retrieved 2026-11-09T04:42:38.658Z